AK104 for locally advanced lung cancer after chemoradiotherapy
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new immunotherapy drug, AK104, for people with stage III non-small cell lung cancer that cannot be removed with surgery. It is for those who have finished chemoradiotherapy and have not gotten worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have stage III non-small cell lung cancer that cannot be surgically removed and you have finished chemoradiotherapy.
- Your cancer does not have certain genetic changes (EGFR, ALK, ROS1).
- You have not had prior immunotherapy or certain targeted drugs.
- You have good overall health (ECOG score 0 or 1).
- You have adequate organ function, no active autoimmune disease, and are not on high-dose steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug called AK104 (cadonilimab) combined with low-dose radiation for people with head and neck or nasopharyngeal cancer that has come back or spread and no longer responds to first treatment. The goal is to see if this combination can shrink tumors or stop them from growing.
This trial studies AK104 along with chemotherapy given before surgery and after surgery for people with resectable (operable) stage II to IIIA non-small cell lung cancer. It aims to improve treatment effectiveness by shrinking the tumor before surgery and helping prevent it from coming back afterward.
This trial tests a new drug called cadonilimab combined with chemotherapy for people with advanced lung cancer who have already tried and failed immunotherapy. It aims to see if this combination can help when standard immunotherapy no longer works.
This trial tests a new drug called AK104 combined with standard chemotherapy and either cetuximab or bevacizumab for people with metastatic colorectal cancer that cannot be surgically removed. It is for those who have had only one prior line of treatment and whose tumors are not MSI-H or have a BRAF mutation.
This trial tests whether adding an immunotherapy drug called Cadonilimab (AK104) to standard chemoradiation can help people with locally advanced cervical cancer that has not spread to distant organs. The goal is to improve treatment outcomes for those who cannot have surgery.
This trial tests two different immunotherapy medicines (AK104 and tislelizumab) combined with chemotherapy as the first treatment for people with advanced lung cancer that hasn't spread to the brain and has low PD-L1. The goal is to see which combination works better and if it helps people live longer.
Hear when a new NSCLC (Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.